Lancet Oncology – Mars 2018

RAPPORT SUR LE RÈGLEMENT PÉDIATRIQUE EUROPÉEN PENDANT DIX ANS ET SON IMPACT SUR LE DÉVELOPPEMENT DE MÉDICAMENTS CONTRE LES CANCERS DES ENFANTS.

Rapport rédigé par : Andrew DJ Pearson, Delphine Heenen, Pamela R Kearns, Anne Goeres, Lynley V Marshall, Patricia Blanc, Gilles Vassal Paediatric and Adolescent Oncology Drug Development, The Royal Marsden NHS Foundation Trust, Sutton, SM2 5PT, UK (ADJP, LM); Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK (ADJP, LM); Innovative Therapy for Children with Cancer, Europe (ADJP, PRK, GV); KickCancer, Brussels, Belgium (DH); Unite 2 Cure, Europe (DH, AG, PB); Cancer Research UK Clinical Trials Unit Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK (PRK); SIOPE Brussels, Belgium (GV, PRK); Foundation Kriibskrank Kanner, Strassen, Luxembourg (AG); Imagine for Margo, Paris, France (PB); and Department of Clinical Research, Gustave Roussy, Paris-Saclay University, Villejuif, France (GV)

Voir l’article